These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 36723667)

  • 1. Synthesis of
    Chen CY; Lu Z; Scattolin T; Chen C; Gan Y; McLaughlin M
    Org Lett; 2023 Feb; 25(6):944-949. PubMed ID: 36723667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced
    Ou SI; Jänne PA; Leal TA; Rybkin II; Sabari JK; Barve MA; Bazhenova L; Johnson ML; Velastegui KL; Cilliers C; Christensen JG; Yan X; Chao RC; Papadopoulos KP
    J Clin Oncol; 2022 Aug; 40(23):2530-2538. PubMed ID: 35167329
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond KRAS(G12C): Biochemical and Computational Characterization of Sotorasib and Adagrasib Binding Specificity and the Critical Role of H95 and Y96.
    Mahran R; Kapp JN; Valtonen S; Champagne A; Ning J; Gillette W; Stephen AG; Hao F; Plückthun A; Härmä H; Pantsar T; Kopra K
    ACS Chem Biol; 2024 Oct; 19(10):2152-2164. PubMed ID: 39283696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adagrasib, a KRAS G12C inhibitor, reverses the multidrug resistance mediated by ABCB1 in vitro and in vivo.
    Zhang Y; Li C; Xia C; Wah To KK; Guo Z; Ren C; Wen L; Wang F; Fu L; Liao N
    Cell Commun Signal; 2022 Sep; 20(1):142. PubMed ID: 36104708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Affinity Measurement of Non-covalent Interactions of the Covalent KRAS G12C GDP Inhibitor MRTX849 to RAS Isoforms Using Surface Plasmon Resonance.
    Alexander P; Stephen AG
    Methods Mol Biol; 2024; 2797():103-114. PubMed ID: 38570455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The KRAS
    Hallin J; Engstrom LD; Hargis L; Calinisan A; Aranda R; Briere DM; Sudhakar N; Bowcut V; Baer BR; Ballard JA; Burkard MR; Fell JB; Fischer JP; Vigers GP; Xue Y; Gatto S; Fernandez-Banet J; Pavlicek A; Velastagui K; Chao RC; Barton J; Pierobon M; Baldelli E; Patricoin EF; Cassidy DP; Marx MA; Rybkin II; Johnson ML; Ou SI; Lito P; Papadopoulos KP; Jänne PA; Olson P; Christensen JG
    Cancer Discov; 2020 Jan; 10(1):54-71. PubMed ID: 31658955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The KRAS
    Briere DM; Li S; Calinisan A; Sudhakar N; Aranda R; Hargis L; Peng DH; Deng J; Engstrom LD; Hallin J; Gatto S; Fernandez-Banet J; Pavlicek A; Wong KK; Christensen JG; Olson P
    Mol Cancer Ther; 2021 Jun; 20(6):975-985. PubMed ID: 33722854
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KRAS G12C fragment screening renders new binding pockets.
    Mathieu M; Steier V; Fassy F; Delorme C; Papin D; Genet B; Duffieux F; Bertrand T; Delarbre L; Le-Borgne H; Parent A; Didier P; Marquette JP; Lowinski M; Houtmann J; Lamberton A; Debussche L; Alexey R
    Small GTPases; 2022 Jan; 13(1):225-238. PubMed ID: 34558391
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adagrasib: First Approval.
    Dhillon S
    Drugs; 2023 Feb; 83(3):275-285. PubMed ID: 36763320
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adagrasib in Non-Small-Cell Lung Cancer Harboring a
    Jänne PA; Riely GJ; Gadgeel SM; Heist RS; Ou SI; Pacheco JM; Johnson ML; Sabari JK; Leventakos K; Yau E; Bazhenova L; Negrao MV; Pennell NA; Zhang J; Anderes K; Der-Torossian H; Kheoh T; Velastegui K; Yan X; Christensen JG; Chao RC; Spira AI
    N Engl J Med; 2022 Jul; 387(2):120-131. PubMed ID: 35658005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C Inhibitors, Sotorasib and Adagrasib, and Overcoming Strategies: Insights From In Vitro Experiments.
    Koga T; Suda K; Fujino T; Ohara S; Hamada A; Nishino M; Chiba M; Shimoji M; Takemoto T; Arita T; Gmachl M; Hofmann MH; Soh J; Mitsudomi T
    J Thorac Oncol; 2021 Aug; 16(8):1321-1332. PubMed ID: 33971321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of the GTPase KRAS
    Xu Q; Zhang G; Liu Q; Li S; Zhang Y
    Expert Opin Ther Pat; 2022 May; 32(5):475-505. PubMed ID: 35062845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The path to the clinic: a comprehensive review on direct KRAS
    Kwan AK; Piazza GA; Keeton AB; Leite CA
    J Exp Clin Cancer Res; 2022 Jan; 41(1):27. PubMed ID: 35045886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adeno-to-squamous transition drives resistance to KRAS inhibition in LKB1 mutant lung cancer.
    Tong X; Patel AS; Kim E; Li H; Chen Y; Li S; Liu S; Dilly J; Kapner KS; Zhang N; Xue Y; Hover L; Mukhopadhyay S; Sherman F; Myndzar K; Sahu P; Gao Y; Li F; Li F; Fang Z; Jin Y; Gao J; Shi M; Sinha S; Chen L; Chen Y; Kheoh T; Yang W; Yanai I; Moreira AL; Velcheti V; Neel BG; Hu L; Christensen JG; Olson P; Gao D; Zhang MQ; Aguirre AJ; Wong KK; Ji H
    Cancer Cell; 2024 Mar; 42(3):413-428.e7. PubMed ID: 38402609
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of Adagrasib (MRTX849) in Brain Metastases: Preclinical Models and Clinical Data from Patients with KRASG12C-Mutant Non-Small Cell Lung Cancer.
    Sabari JK; Velcheti V; Shimizu K; Strickland MR; Heist RS; Singh M; Nayyar N; Giobbie-Hurder A; Digumarthy SR; Gainor JF; Rajan AP; Nieblas-Bedolla E; Burns AC; Hallin J; Olson P; Christensen JG; Kurz SC; Brastianos PK; Wakimoto H
    Clin Cancer Res; 2022 Aug; 28(15):3318-3328. PubMed ID: 35404402
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Remodeling of the tumor/tumor microenvironment ecosystem during KRAS G12C inhibitor clinical resistance in lung cancer.
    Manabe T; Bivona TG
    J Clin Invest; 2022 Feb; 132(4):. PubMed ID: 35166243
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Kras
    Christensen JG; Olson P; Briere T; Wiel C; Bergo MO
    J Intern Med; 2020 Aug; 288(2):183-191. PubMed ID: 32176377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and Intracranial Activity of Adagrasib in Patients With
    Bernstein E; Luo J; Wang K; Negrao MV; Jänne PA; Sabari JK
    JCO Precis Oncol; 2024 Feb; 8():e2300447. PubMed ID: 38330263
    [No Abstract]   [Full Text] [Related]  

  • 19.
    Tu G; Liu Q; Qiu Y; Leung EL; Yao X
    Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430323
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Ceddia S; Landi L; Cappuzzo F
    Int J Mol Sci; 2022 Aug; 23(16):. PubMed ID: 36012655
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.